These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1077 related items for PubMed ID: 22177371

  • 1. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 3. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM, Williams J.
    Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian COPD Study Investigators.
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [Abstract] [Full Text] [Related]

  • 5. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
    Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B.
    COPD; 2012 Dec 15; 9(6):629-36. PubMed ID: 23020650
    [Abstract] [Full Text] [Related]

  • 7. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
    Bleecker ER, Siler T, Owen R, Kramer B.
    Int J Chron Obstruct Pulmon Dis; 2011 Dec 15; 6():431-8. PubMed ID: 22003288
    [Abstract] [Full Text] [Related]

  • 8. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.
    Respir Med; 2013 Feb 15; 107(2):223-32. PubMed ID: 23219347
    [Abstract] [Full Text] [Related]

  • 9. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B, INTEGRAL Study Investigators.
    Pulm Pharmacol Ther; 2011 Feb 15; 24(1):162-8. PubMed ID: 20619353
    [Abstract] [Full Text] [Related]

  • 10. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
    Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B, INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators.
    Eur Respir J; 2011 Feb 15; 37(2):273-9. PubMed ID: 20693243
    [Abstract] [Full Text] [Related]

  • 11. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
    Decramer M, Rossi A, Lawrence D, McBryan D.
    Respir Med; 2012 Dec 15; 106(12):1706-14. PubMed ID: 23031496
    [Abstract] [Full Text] [Related]

  • 12. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
    To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, Kramer B.
    Respir Med; 2012 Dec 15; 106(12):1715-21. PubMed ID: 23040786
    [Abstract] [Full Text] [Related]

  • 13. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
    Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B, INTENSITY study investigators.
    Eur Respir J; 2011 Oct 15; 38(4):797-803. PubMed ID: 21622587
    [Abstract] [Full Text] [Related]

  • 14. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ, Yoon HK, Park MJ, Yoo KH, Jung KS, Park JW, Lim SY, Shim JJ, Lee YC, Kim YS, Oh YM, Kim S, Yoo CG.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 15; 12():1589-1596. PubMed ID: 28615931
    [Abstract] [Full Text] [Related]

  • 15. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B.
    Ther Adv Respir Dis; 2011 Oct 15; 5(5):345-57. PubMed ID: 21719531
    [Abstract] [Full Text] [Related]

  • 16. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.
    Pulm Pharmacol Ther; 2007 Oct 15; 20(6):740-9. PubMed ID: 17088091
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.
    Int J Chron Obstruct Pulmon Dis; 2014 Oct 15; 9():215-28. PubMed ID: 24596459
    [Abstract] [Full Text] [Related]

  • 18. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA, Buhl R, Lawrence D, Young D.
    Respir Med; 2015 Jan 15; 109(1):105-11. PubMed ID: 25433954
    [Abstract] [Full Text] [Related]

  • 19. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
    Jones PW, Mahler DA, Gale R, Owen R, Kramer B.
    Respir Med; 2011 Jun 15; 105(6):892-9. PubMed ID: 21397482
    [Abstract] [Full Text] [Related]

  • 20. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG.
    Respir Med; 2013 Jan 15; 107(1):107-11. PubMed ID: 23083839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.